The Global Gunshot Injuries Treatment Market, estimated at USD 16.3 Mn in 2026, is expected to exhibit a CAGR of 8.2% and reach USD 28.2 Mn by 2033.
The Global Gunshot Injuries Treatment Market was valued at USD 16.3 Million in 2026 and is projected to exhibit a CAGR of 8.2% over the forecast period (2026–2033). Technological developments such as innovative pocket-sized device, which use tiny sponges and emergency treatment in the battlefield for soldiers, are expected to be major factors driving growth of the global gunshot injuries treatment market over the foreseeable future. Efficient treatment by products that prevent postpartum hemorrhage to boost the gunshot injuries treatment market Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in low-income countries, and responsible for a quarter of all maternal deaths globally.
According to an article published by Medscape, pregnancy-related mortality ratio was estimated to be 17.3 deaths per 100,000 pregnant women, with around 11.4% of these deaths caused due by postpartum hemorrhage, in 2013. The initiatives taken by organizations such as the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the UK Government to aid research for the development of preventive devices for PPH is a major factor causing expansion of the gunshot injuries treatment market. Furthermore, the development of the XSTAT-PPH device by Oregon Health & Science Univsersity and RevMedx for the treatment of postpartum hemorrhage (PPH) in low resource settings accelerates growth of the gunshot injuries treatment market.
To know the latest trends and insights prevalent in the gunshot injuries treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/gunshot-injuries-treatment-market-772
Surgical priorities for prevention of gunshot management includes hemorrhage control, prevention, and reconstruction of infection, as gunshot has potential to damage affected tissues. The Xstat syringe was the only FDA-approved device for immediate treatment of blood flow. According to an article published in Current Reviews in Musculoskeletal Medicine, in 2015, around 70% of battlefield wounds sustained in conflict since the Second World War were gunshot injuries during the early phases of conflicts. Furthermore, affected soldiers require immediate transfer to trauma center for definitive management for conducting initial care and stabilization in emergency department.
Key takeaways of the Gunshot Injuries Treatment Market
- The global gunshot injuries treatment market is expected to exhibit a CAGR of 8.2% over the forecast period, with economies in Asia Pacific, Latin America, Middle East, and Africa focusing on increasing their military spending.
- The Xstat is the dominant product segment in the market, as this portable device provides emergency treatment for soldiers in the battlefield
- RevMedx, Inc currently is the only player involved in the global gunshot injuries treatment market.
Key News
- In June 2026, researchers from military and surgical medical centers reported a peptide-based therapy to speed recovery after gunshot and shrapnel injuries. The approach uses active vascular peptides, earlier used for chronic ischemia, to protect blood vessels, improve vascular function, and restore vascular integrity after surgery. Early clinical cases showed promising results, with preliminary estimates suggesting tissue repair could accelerate by at least 1.5 times, pending larger studies for confirmation.
- In July 2026, KAIST introduced a spray-on hemostatic powder for severe bleeding control. The AGCL powder turns into a strong hydrogel within about one second after contact with blood, helping seal deep, irregular, and battlefield-type wounds. The technology is designed for soldiers, emergency responders, ambulances, disaster care, and hospital trauma settings.
- In March 2026, Cresilon, Inc., biotechnology company received a Vizient Innovative Technology contract for TRAUMAGEL, its FDA-cleared, plant-based hemostatic gel for temporary external control of moderate to severe bleeding. Supplied in a 30 mL pre-filled sterile syringe, the gel supports rapid hemorrhage control for EMS agencies, trauma hospitals, military, and law enforcement users. The award expands hospital access and reinforces TRAUMAGEL’s role in emergency bleeding management across nationwide emergency and acute care settings. (Source: Cresilon, Inc.)
- In February 2026, researchers proposed a wearable robotic vest for hemorrhage suppression. The system uses a shape-adjustable ring and inflatable airbag mechanism to apply constant pressure over severe bleeding sites, including difficult non-extremity areas such as the abdomen, back, and neck. The device was tested on casualty simulation kits and showed potential for emergency trauma response.
Contact Us